Oncology Xagena

Xagena Mappa
Xagena Newsletter
Xagena Salute

Metastatic melanoma: single-agent versus combination therapy

The advent of new immunotherapies for the treatment of metastatic melanoma has resulted in various novel combination strategies. Because of their distinct modes of action, different immunotherapies have been investigated in combination with one another, as well as combined with targeted therapies and other treatment modalities. Areas covered: anti-CTLA-4 and anti-PD-1 treatments enhance antitumor immunity through complementary and non-redundant mechanisms.

The combination of the anti-CTLA-4 agent Ipilimumab ( Yervoy ) and the anti-PD-1 agent Nivolumab ( Opdivo ) has been shown to improve progression-free survival and objective response rate compared with either agent alone as monotherapy in patients with advanced melanoma.
However, the combination was associated with significant toxicity, with around one-third of patients discontinuing treatment as a result.

The sequential use of Nivolumab and Ipilimumab was associated with similar outcomes and comparable toxicity to concurrent therapy.

Clinical trials assessing various combinations of immunomodulating antibodies are ongoing or planned.

Ipilimumab and Pembrolizumab ( Keytruda ) have also been investigated in combination with the oncolytic virus, Talimogene laherparepvec ( T-VEC; Imlygic ), with promising results.

In addition, immunotherapies have also been combined with chemotherapy, radiotherapy and electrochemotherapy.

Investigation of combination approaches represents the start of a new story that begins with melanoma treatment and expands to embrace other solid and hematological cancers. ( Xagena )

Grimaldi AM et al, Expert Opin Biol Ther 2016:1-9